



## Health

Public Health  
4<sup>th</sup> Floor; 300 Carlton Street Winnipeg MB R3B 3M9  
[vaccines@gov.mb.ca](mailto:vaccines@gov.mb.ca)

December 9, 2022

### **Re: Updated Clinical Recommendations on Concurrent Administration of Vaccines for Children 6 months to 4 years old and Management of Radiocontrast Allergies and COVID-19 Vaccine Administration**

Dear Health Care Provider:

Please note important updates to the following:

#### **1. Co-Administration of Vaccines in those 6 months to 4 years of Age**

The National Advisory Committee on Immunization (NACI) has updated recommendations for children 6 months to 4 years of age to support the administration of COVID-19 vaccines concurrently, or any time before or after, non-COVID-19 vaccines (including live and non-live vaccines)

Recommendations from the National Advisory Committee on Immunizations (NACI) on the concurrent administration of COVID and non-COVID vaccines in the 6 months to 4 years age cohort are available at: <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html>

#### **2. Managing Clients with Allergies to Radiocontrast Material and COVID-19 Vaccines**

Tromethamine (trometamol or Tris) may be found in certain medications and some radiocontrast media. It has been identified as a potential allergen in COVID-19 mRNA vaccines.

People who report an allergy to contrast material (CT dye), including gadolinium, can be immunized with vaccines containing Tromethamine (trometamol or Tris). However, **they should be observed for 30 minutes post immunization.**

People who have a known allergy specifically to Tromethamine (trometamol or Tris), or have experienced an allergic reaction after receipt of a COVID-19 mRNA vaccine should be referred to an allergist for further assessment.

Please refer to the guidance document from the Canadian Society of Allergy and Clinical Immunology for more information: [2021-04-10 UPDATE - COVID-19 Vaccine Testing & Administration Guidance \(csaci.ca\)](#)

Please share this information with all relevant colleagues in your facility/clinic.

Sincerely,

*“Original Signed By”*

Richard Baydack, PhD  
Director  
Communicable Disease Control

*“Original Signed By”*

Davinder Singh, MD, MSc, FRCPC  
Medical Lead, Vaccines  
Communicable Disease Control